This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow 30 Stock Roundup: Cisco to Buy Acacia, Microsoft & ServiceNow Partnernership
by Swarup Gupta
The index endured a turbulent week but gained after the Fed Chair indicated that a rate was likely later this month.
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
by Kinjel Shah
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?
by Zacks Equity Research
J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $141.23, marking a -0.13% move from the previous day.
Bayer-J&J Announce Positive Xarelto Data in Children with VTE
by Zacks Equity Research
Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Johnson & Johnson (JNJ) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
by Zacks Equity Research
Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.
Intra-Cellular Therapies' Candidate Fails in Phase III Study
by Zacks Equity Research
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Dow 30 Stock Roundup: Visa to Buy Verifi, Goldman May Launch Own Cryptocurrency
by Swarup Gupta
The index enjoyed a holiday-shortened but successful week, buoyed by rate cut hopes and a reduction in trade tensions.
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
by Zacks Equity Research
Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $140.03, moving +0.48% from the previous trading session.
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma
by Zacks Equity Research
Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Pacira Gets EMA Acceptance for Pain Management Drug Exparel
by Zacks Equity Research
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $144.24, moving +0.82% from the previous trading session.
Axsome Initiates Phase III Study on Depression Candidate
by Zacks Equity Research
Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
by Swarup Gupta
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $139.44, moving -0.46% from the previous trading session.